T1	Participants 83 131	patients with advanced nasopharyngeal carcinoma:
T2	Participants 281 334	patients with advanced nasopharyngeal carcinoma (NPC)
T3	Participants 344 386	Two hundred patients with stage III/IV NPC
T4	Participants 475 504	Patients in the control group
T5	Participants 863 878	treatment group
T6	Participants 936 949	control group
T7	Participants 1001 1016	treatment group
T8	Participants 1044 1057	control group
T9	Participants 1486 1512	patients with advanced NPC
